Literature DB >> 12946796

Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression.

David H Gorski1, Alejandro D Leal, James S Goydos.   

Abstract

Vascular endothelial growth factor-A (VEGF-A) is an important mediator of angiogenesis in normal and neoplastic tissues. Total VEGF-A levels have been associated with melanoma progression, but the relative contributions of each isoform is unknown. To determine whether differences in the production of any or all of the major VEGF-A isoforms are related to stage of progression, we compared message levels for the three major isoforms of VEGF in melanoma specimens from different stages of progression.Primary melanomas (N = 18), primary recurrences (N = 5), regional dermal metastases (N = 11), nodal metastases (N = 12), normal lymph nodes (N = 18), and distant metastases (N = 9) were prospectively collected. Samples from the horizontal and vertical growth phases of primary tumors were also collected from five additional patients. Message levels for the three major VEGF-A isoforms were measured using real-time quantitative reverse-transcriptase polymerase chain reaction and normalized to beta-actin mRNA levels. There was a marked increase in the expression of all three VEGF-A isoforms from the vertical growth phase tissue as compared with the horizontal growth phase tissue. Primary tumors, local recurrences, regional dermal metastases, nodal metastases, and distant metastases all produced more VEGF(121) and VEGF(165) than negative nodes. Nodal metastases produced the highest level of these two isoforms, higher even than distant metastases. There was no significant difference in VEGF(189) message among the groups. Melanomas in the vertical growth phase produce more VEGF-A (all isoforms) than in the horizontal growth phase. Nodal metastases produce the highest levels of VEGF(121) and VEGF(165), but not VEGF(189) as compared with other stages of progression. These data suggest that the soluble forms of VEGF-A might be an important factor in melanoma metastasis to regional lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946796     DOI: 10.1016/S1072-7515(03)00388-0

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  18 in total

1.  Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection.

Authors:  H M C Shantha Kumara; Jenny C Cabot; Xiaohong Yan; Sonali A C Herath; Martin Luchtefeld; Matthew F Kalady; Daniel L Feingold; Raymond Baxter; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-12-24       Impact factor: 4.584

2.  Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5.

Authors:  Yun Chen; David H Gorski
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

3.  Functional significance of VEGFR-2 on ovarian cancer cells.

Authors:  Whitney A Spannuth; Alpa M Nick; Nicholas B Jennings; Guillermo N Armaiz-Pena; Lingegowda S Mangala; Christopher G Danes; Yvonne G Lin; William M Merritt; Premal H Thaker; Aparna A Kamat; Liz Y Han; James R Tonra; Robert L Coleman; Lee M Ellis; Anil K Sood
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

4.  A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.

Authors:  Valerie P Grignol; Thomas Olencki; Kiran Relekar; Cynthia Taylor; Amanda Kibler; Cheryl Kefauver; Lai Wei; Michael J Walker; Helen X Chen; Kari Kendra; William E Carson
Journal:  J Immunother       Date:  2011 Jul-Aug       Impact factor: 4.456

5.  BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

Authors:  Kevin B Kim; Jeffrey A Sosman; John P Fruehauf; Gerald P Linette; Svetomir N Markovic; David F McDermott; Jeffrey S Weber; Hoa Nguyen; Peter Cheverton; Daniel Chen; Amy C Peterson; William E Carson; Steven J O'Day
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

6.  The homeobox gene GAX activates p21WAF1/CIP1 expression in vascular endothelial cells through direct interaction with upstream AT-rich sequences.

Authors:  Yun Chen; Alejandro D Leal; Sejal Patel; David H Gorski
Journal:  J Biol Chem       Date:  2006-10-30       Impact factor: 5.157

7.  Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells.

Authors:  Takayuki Yoshizaki; Wataru Motomura; Sachie Tanno; Shima Kumei; Yumiko Yoshizaki; Satoshi Tanno; Toshikatsu Okumura
Journal:  J Exp Clin Cancer Res       Date:  2010-03-10

8.  Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.

Authors:  Timothy D Solberg; Jessica Nearman; John Mullins; Sicong Li; Janina Baranowska-Kortylewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-01       Impact factor: 7.038

Review 9.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

10.  VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines.

Authors:  Ene T Raig; Natalie B Jones; Kimberly A Varker; Kristen Benniger; Michael R Go; Jennifer L Biber; Gregory B Lesinski; William E Carson
Journal:  J Interferon Cytokine Res       Date:  2008-09       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.